コンテンツにジャンプ

トップページ > グループ紹介 > 新薬開発分野（柏） > 業績

業績

2026年

  1. Takashima H, Tsumura R, Koga Y, Anzai T, Yin X, Sato N, Shigekawa Y, Kanayama Y, Nambu A, Usuda S, Haba H, Sakashita S, Inaki A, Manabe S, Yasunaga M.Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 Radioimmunotherapy. Mol Pharm. 2026, 23(4):2422-2435.
  2. Itsukaichi M, Yasunaga M. Advanced Evaluation of T-Cell-Dependent Bispecific Antibodies Using Fluorescence Imaging and In Vivo Models. Methods Mol Biol. 2026;2997:163-173.
  3. Oka M, Itsukaichi M, Yasunaga M. Optimized In Vitro T-Cell Exhaustion Assay for Evaluating T-Cell-Dependent Bispecific Antibodies. Methods Mol Biol. 2026;2997:151-161.
  4. Nakamura Y, Azuma T, Yasunaga M.  Fluorescent-Based Analysis of T Cells and T-Cell-Dependent Bispecific Antibody in a Brain Tumor Mouse Model. Methods Mol Biol. 2026;2997:175-186.
  5. Nakamura R, Tsumura R, Anzai T, Asano R, Yasunaga M. Visualization of Immunological Synapse Formation by Intercellular Cross-Linking of T Cell-Dependent Bispecific Antibodies Using Fluorescence Microscopy.
    Methods Mol Biol. 2026;2997:135-142.
  6. Nakamura R, Tsumura R, Anzai T, Asano R, Yasunaga M. Measurement of T Cell Migration by T Cell-Dependent Bispecific Antibody in Cancer Cells and T Cell Cross-Linking. Methods Mol Biol. 2026;2997:143-149.
  7. Anzai T, Yasunaga M. Laboratory-Scale Production of Recombinant IgG Antibodies. Methods Mol Biol. 2026;2997:119-131
  8. Tsumura R, Uchida A, Yasunaga M. Peripheral Blood Mononuclear Cell (PBMC) Humanized Mice as a Platform for a Preclinical In Vivo Evaluation of T-Cell-Dependent Bispecific Antibodies. Methods Mol Biol. 2026;2997:187-202.

2025年

  1. Koganemaru S, Fuchigami H, Morizono C, Shinohara H, Kuboki Y, Furuuchi K, Uenaka T, Doi T, Yasunaga M. Potential Mechanisms of Interstitial Lung Disease Induced by Antibody-Drug Conjugates Based on Quantitative Analysis of Drug Distribution. Mol Cancer Ther. 2025, 24(2):242-250.
  2. Nakamura R, Tsumura R, Anzai T, Asano R, Yasunaga M.Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity.
    Cancer Immunol Immunother. 2025, 74(8):246.
  3. Sasabe M, Takashima K, Sakashita S, Koga Y, Anzai T, Yang S, Saijou S, Ishikawa A, Yamaguchi T, Tanaka H, Yoda Y, Fujita T, Mitsunaga S, Yasunaga M, Yano T.Near-Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti-EpCAM Antibody. Cancer Sci. 2025, 116(12):3388-3402.
  4. Fuse Y, Sasaki E, Tamaki M, Kawamura S, Ohno H, Yamada S, Yasunaga M, Takakura H, Hanaoka H, Kobayashi H, Nakasone H, Hanaoka K.Development of a silicon phthalocyanine analogue for near-infrared photoimmunotherapy and its application to HTLV-1-infected leukemic cells. RSC Chem Biol. 2025, 6(10):1576-1584.
  5. Miura D, Kato Y, Yasunaga M, Kumagai I, Asano R. Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy. J Biol Eng. 2025,19(1):45.

2024年

  1. Koganemaru S, Fuchigami H, Yamashita H, Morizono C, Sunakawa H, Kawazoe A, Nakamura Y, Kuboki Y, Shitara K, Yano T, Doi T, Yasunaga M.Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry. Clin Pharmacol Ther. 2024, 115(1):62-70.
  2. Tsumura R, Anzai T, Koga Y, Takashima H, Matsumura Y, Yasunaga M. Anti-tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models. Cancer Sci. 2024, 115(12):3986-3996.
  3. Tanaka H, Koga Y, Sugahara M, Fuchigami H, Ishikawa A, Yamaguchi T, Banba A, Shinozaki T, Matsuura K, Hayashi R, Sakashita S, Yasunaga M, Yano T.Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy. Pharmaceuticals (Basel). 2024, 17(9):1246.

2023年

  1. Koganemaru S, Kawai T, Fuchigami H, Maeda N, Koyama K, Kuboki Y, Mukohara T, Doi T, Yasunaga M.Quantitative analysis of drug distribution in heterogeneous tissues using dual-stacking capillary electrophoresis-mass spectrometry. Br J Pharmacol. 2023, 180(6):762-774.
  2. Expansion of mixed immune cells using CD3/CD161 co-stimulation for the treatment of cancer.
    Tsumura R, Haruta M, Kuwano M, Yasunaga M. Sci Rep. 2023, 13(1):6803.
  3. Takashima H, Ohnuki K, Manabe S, Koga Y, Tsumura R, Anzai T, Wang Y, Yin X, Sato N, Shigekawa Y, Nambu A, Usuda S, Haba H, Fujii H, Yasunaga M. Tumor Targeting of 211At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. Mol Pharm. 2023, 20(2):1156-1167.
  4. Fujii T, Ito K, Takahashi K, Aoki T, Takasugi R, Seki T, Iwai Y, Watanabe T, Hirama R, Tsumura R, Fuchigami H, Yasunaga M, Matsuda Y.Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation. ACS Med Chem Lett. 2023, 14(12):1767-1773.
  5. Hiranyakorn M, Iwamoto S, Hoshinoo A, Tsumura R, Takashima H, Yasunaga M, Manabe S.Chromatographic Analysis of the N-Glycan Profile on Therapeutic Antibodies Using FcγRIIIa Affinity Column Chromatography. ACS Omega. 2023, 8(18):16513-16518.

2022年

  1. Anzai T, Saijou S, Takashima H, Hara M, Hanaoka S, Matsumura Y, Yasunaga M. Identification of CD73 as the Antigen of an Antigen-Unknown Monoclonal Antibody Established by Exosome Immunization, and Its Antibody-Drug Conjugate Exerts an Antitumor Effect on Glioblastoma Cell Lines. Pharmaceuticals (Basel). 2022, 15(7):837.
  2. Takashima K, Koga Y, Anzai T, Migita K, Yamaguchi T, Ishikawa A, Sakashita S, Yasunaga M, Yano T. Evaluation of Fluorescence Intensity and Antitumor Effect Using Real-Time Imaging in Photoimmunotherapy. Pharmaceuticals (Basel). 2022, 15(2):223.
  3. Ohnuki K, Yoshimoto M, Haba H, Manabe S, Takashima H, Yasunaga M, Takenaka Y, Fujii H. Protection from contamination by 211At, an enigmatic but promising alpha-particle-emitting radionuclide. EJNMMI Phys. 2022, 9(1):39.
  4. Takakusagi Y, Sugyo A, Tsuji AB, Sudo H, Yasunaga M, Matsumura Y, Sugawara F, Sakaguchi K, Higashi T. The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3. Transl Oncol. 2022, 15(1):101285.

2021年

  1. Takashima H, Koga Y, Manabe S, Ohnuki K, Tsumura R, Anzai T, Iwata N, Wang Y, Yokokita T, Komori Y, Mori D, Usuda S, Haba H, Fujii H, Matsumura Y, Yasunaga M. Radioimmunotherapy with an 211 At-labeled anti-tissue factor antibody protected by sodium ascorbate. Cancer Sci. 2021, 112(5):1975-1986.
  2. Kamakura D, Asano R, Yasunaga M. T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals (Basel). 2021, 14(11):1172.
  3. Manabe S, Takashima H, Ohnuki K, Koga Y, Tsumura R, Iwata N, Wang Y, Yokokita T, Komori Y, Usuda S, Mori D, Haba H, Fujii H, Yasunaga M, Matsumura Y. Stabilization of an 211At-Labeled Antibody with Sodium Ascorbate. ACS Omega. 2021, 6(23):14887-14895.
  4. Anzai T, Saijou S, Ohnuki Y, Kurosawa H, Yasunaga M, Matsumura Y. TMEM180 contributes to SW480 human colorectal cancer cell proliferation through intra-cellular metabolic pathways. Transl Oncol. 2021, 14(10):101186.
  5. Tsumura R, Anzai T, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Antitumor effect of humanized anti‑tissue factor antibody‑drug conjugate in a model of peritoneal disseminated pancreatic cancer. Oncol Rep. 2021, 45(1):329-336.
  6. Shiraishi T, Ikeda K, Tsukada Y, Nishizawa Y, Sasaki T, Ito M, Kojima M, Ishii G, Tsumura R, Saijou S, Koga Y, Yasunaga M, Matsumura Y. High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer. BMC Cancer. 2021, 21(1):302.
新薬開発分野（柏）
主な研究内容
メンバー
業績
共同研究プロポーザル
お問い合わせ
  • EPOC研究者一覧NEW